ArticleCureus2025
Pilot Randomized Trial Exploring the Impacts of Deceased Donor Kidney Procurement Biopsies on Organ Evaluation and Transplant Outcomes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Preimplantation Histopathologic Assessment of Deceased Donor Kidneys: Recommendations from the Banff Time-Zero Biopsy Working Group.Journal of the American Society of Nephrology : JASN · 2025Guideline
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKidney biopsies obtained at the time of organ procurement are often used in evaluating deceased donor (DD) kidneys. We conducted a pilot randomized controlled trial (RCT) to help assess the feasibility and impact of deferring procurement biopsy information at the time of organ offer. METHODOLOGY: This pilot RCT involved one Midwestern Organ Procurement Organization (OPO) and two local transplant centers in the United States. Waitlisted transplant candidates were approached between July 01, 2019, and May 31, 2022, for consent to receive a kidney from a randomized DD if an offer arose. Criteria for DD randomization to immediate frozen biopsy or permanent section processing (delayed biopsy information) were based on factors used for routine biopsy at the time. Outcomes were assessed through linked registry data.
resultsOf 408 transplant candidates approached, 85 (20.1%) consented to receive a kidney from a randomized DD, if available. Substantial effort was invested in candidate recruitment and consent. Consented candidates disenrolled for reasons including living donor transplantation (9/85, 10.5%), receiving an imported, previously biopsied kidney (11/85, 12.9%), DD outside biopsy criteria (18/85, 21.2%), or immediate frozen biopsy requested (5/85, 5.9%). Eleven randomized DD yielded 12 transplants (6 kidneys from 5 donors in each arm), with a median kidney donor profile index of 49 in the frozen section arm and 54 in the permanent section arm. Biopsy results were similar between arms (median glomerulosclerosis 3.4% vs. 9.9%;
conclusionsThis pilot RCT did not suggest concerns for delayed DD kidney biopsy information on organ use or transplant outcomes. However, the randomized sample was small, underpowered, and comprised intermediate-risk donors. Trial conduct required considerable effort and faced a high disenrollment rate. Substantial expansion would be required to detect clinically significant differences in outcomes in future trials. Building evidence on the role of kidney procurement biopsies may require national collaboration and consideration of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.